The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Complement activation plays a key role in the side‐effects of rituximab treatment
Open accessAbstract
Treatment with rituximab, a chimaeric anti‐CD20 monoclonal antibody, can be associated with moderate to severe first‐dose side‐effects, notably in patients with high numbers of circulating tumour cells. The aim of this study was to elucidate the mechanism of these side‐effects. At multiple early time points during the first infusion of rituximab, complement activation products (C3b/c and C4b/c) and cytokines [tumour necrosis factor alpha (TNF‐α), interleukin 6 (IL‐6) and IL‐8] were measured in five relapsed low‐grade non‐Hodgkin's lymphoma (NHL) patients. Infusion of rituximab induced rapid complement activation, preceding the release of TNF‐α, IL‐6 and IL‐8. Although the study group was small, the level of complement activation appeared to be correlated both with the number of circulating B cells prior to the infusion (r = 0·85; P = 0·07) and with the severity of the side‐effects. We conclude that complement plays a pivotal role in the pathogenesis of side‐effects of rituximab treatment. As complement activation can not be prevented by corticosteroids, it might be relevant to study the possible role of complement inhibitors during the first administration of rituximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“However, other studies showed the importance of FcgR mechanisms for the efficacy of rituximab (Clynes et al, 2000).”
BackgroundMcLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Self-citationCoiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
Davis, T. A., White, C. A., Grillo-López, A. J., Velasquez, W. S., Link, B. K., Maloney, D. G., Dillman, R. O., Williams, M. E., Mohrbacher, A., Weaver, R. L., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1851 · Cited by 290
Self-citationByrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264
Harjunpää, Junnikkala, & Meri (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00745.x · Cited by 256
Hack, C. E., Ogilvie, A. C., Eisele, B., Eerenberg, A. J. M., Wagstaff, J., & THIJS, L. G. (1993) · Intensive Care Medicine · doi:10.1007/bf01738946 · Cited by 105
Self-citationJansen, N. J. G., Vanoeveren, W., VANVLIET, M., Stoutenbeek, C. P., Eysman, L., & Wildevuur, C. R. H. (1991) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/1010-7940(91)90032-f · Cited by 104
Cited by
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Ishida, T., Joh, T., Uike, N., Yamamoto, K., Utsunomiya, A., Yoshida, S., Saburi, Y., Miyamoto, T., Takemoto, S., Suzushima, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3472 · Cited by 657
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Metadata
- Authors
- Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 115
- Issue
- 4
- Pages
- 807-811
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2115351802
- Cited by
- 327
- References
- 12
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement activation plays a key role in the side‐effects of rituximab treatment. https://app.cochat.ai/papers/10.1046/j.1365-2141.2001.03166.x
- The paper
- Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001). Complement activation plays a key role in the side‐effects of rituximab treatment. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.2001.03166.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.